Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 12
Submit an article Journal homepage
202
Views
10
CrossRef citations to date
0
Altmetric
Letter to the editor

Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy

Xin-Xin CaoDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;
,
Tao WangDepartment of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
,
Yue-Hua LiuDepartment of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
,
Dao-bin ZhouDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;
&
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Correspondence[email protected]
Pages 2934-2936 | Received 13 Feb 2016, Accepted 04 Apr 2016, Published online: 27 Apr 2016

References

  • Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273–281.
  • Gabriel SE, Perry HO, Oleson GB, et al. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67:58–65.
  • Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33:37–43.
  • Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69:66–72.
  • Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87:10–20.
  • Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, et al. Clinical characteristics, outcome of scleromyxedema: a retrospective multicenter study. Ann Dermatol Venereol. 2010;137:782–788.
  • Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol. 2004;140:277–280.
  • Kulczycki A, Nelson M, Eisen A, et al. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol. 2003;149:1276–1281.
  • Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo clinic experience. Mayo Clin Proc. 2005;80:41–47.
  • Keong CH, Asaka Y, Fukuro S, et al . Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990;22:842–844.
  • Kuldeep CM, Mittal AK, Gupta LK, et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2005;71:44–45.
  • Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004;51:S120–S123.
  • Cañueto J, Labrador J, Román C, et al . The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol. 2012;88:450–454.
  • Donato ML, Feasel AM, Weber DM, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107:463–466.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.